Contrive Datum Insights has published "Artificial Vascular Grafts Market Size, Share & Industry Analysis, By Product (Endovascular Stent Graft, Hemodialysis Access Graft, Peripheral Vascular Graft, Coronary Artery By-pass Graft), Raw material (Synthetic Raw Material, Biological Raw Material), Application (Aneurysms, Kidney Failure, Vascular Occlusion, Coronary Artery Diseases, Other Applications), End user (Hospitals, Ambulatory Surgical Centers, Specialty Cardiac & Vascular Centers), Distribution channel (Direct / Institutional Tenders, Third-Party Distributors), and Regional Forecast, 2026-2034". The study sizes the global artificial vascular grafts market at USD 2.05 billion in 2025 and projects growth from USD 2.2 billion in 2026 to USD 3.89 billion by 2034, a compound annual growth rate of 7.38% across the forecast period.
Artificial vascular grafts are prosthetic or biologically derived tubular conduits implanted to replace or bypass diseased, damaged or occluded blood vessels. They are manufactured from synthetic polymers such as expanded polytetrafluoroethylene and polyester, or from processed biological tissue, and are supplied in a range of diameters and lengths to match the vessel being repaired. Buyers include vascular and cardiac surgeons, interventional radiologists and hospital procurement teams who select a graft based on the procedure being performed, whether hemodialysis access creation, aneurysm repair, peripheral bypass or coronary bypass surgery.
Rising end-stage renal disease burden lifting hemodialysis access graft demand
Rising end-stage renal disease burden lifting hemodialysis access graft demand is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 7.38% a year, the product lines exposed to it move fastest: Endovascular Stent Graft compounds at 8.65%, taking its share of revenue from 37.56% to 41.9% and its value from USD 0.77 billion to USD 1.63 billion.
On the upside, the study's bull case assumes endovascular aneurysm repair adoption accelerates faster than the base case as reimbursement broadens across more countries, and hemodialysis access volumes grow with an aging dialysis population without a matching rise in arteriovenous fistula substitution, which would take 2034 revenue to USD 4.51 billion against the USD 3.89 billion base case.
The downside is specific. Adoption of endovascular repair slows as tender-based pricing pressure compresses supplier margins and hospitals delay procedure volume growth, while arteriovenous fistula remains the preferred lower-cost option for a larger share of dialysis patients, and 2034 revenue lands at USD 3.37 billion. Hemodialysis Access Graft is the drag, 30.24% of the 2025 base compounding at 6.96% while the market runs at 7.38%.
Where the Competition Actually Sits
Competition in the global artificial vascular grafts market runs along the product axis, not the regional one, and it concentrates on a single line. Endovascular Stent Graft is both the largest position, at 37.56% of 2025 revenue and USD 0.77 billion, and the fastest-growing, at 8.65%, taking it to 41.9% by 2034. A supplier without a position there is competing for a shrinking share of a market worth USD 2.05 billion.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Raw material | Synthetic Raw Material | 78.05% · USD 1.6 billion | Biological Raw Material 9.4% |
| Application | Aneurysms | 36.1% · USD 0.74 billion | — |
| End user | Hospitals | 67.8% · USD 1.39 billion | Ambulatory Surgical Centers 10.04% |
| Distribution channel | Direct / Institutional Tenders | 63.9% · USD 1.31 billion | Third-Party Distributors 8.32% |
- Regionally, the lead sits with North America: 38.54% of 2025 global revenue, USD 0.79 billion rising to USD 1.32 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 23.9% in 2025 to 30.08% in 2034, with revenue growing from USD 0.49 billion to USD 1.17 billion.
- Middle East and Africa stays the smallest contributor across the period: 4.88% of revenue in 2025 and 4.63% in 2034.
- By product, the largest line in 2025 was Endovascular Stent Graft, at 37.56% of revenue and USD 0.77 billion.
- The fastest product line is Endovascular Stent Graft, forecast to compound at 8.65% through the period.
- The United States is the largest single country market at USD 0.65 billion in 2025, 31.71% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by product, and by raw material, application, end user and distribution channel. The headline total carries bear, base and bull cases at USD 3.37 billion and USD 4.51 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.